

chain nodes :
 1 2 3 4 7 8 9 10 11 12 13 14 15 16 17 21 22 23
 ring nodes :
 5 6 18 19 20
 chain bonds :
 1-2 1-17 1-23 2-3 3-4 3-21 4-5 4-16 6-7 7-8 7-15 8-9 9-10 9-14 10-11 10-13
 11-12 11-22
 ring bonds :
 5-6 5-19 6-18 18-20 19-20
 exact/norm bonds :
 1-2 1-17 1-23 2-3 3-21 4-5 4-16 5-6 5-19 6-18 7-8 7-15 8-9 9-14 10-13
 11-12 11-22 18-20 19-20
 exact bonds :
 3-4 6-7 9-10 10-11

G2:Cb,n-Bu,i-Bu,s-Bu,t-Bu

G3:Cb,n-Bu,i-Bu,s-Bu,t-Bu

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom
 20:Atom 21:CLASS 22:CLASS 23:CLASS

L3

2 L2

=> d ab bib hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
 AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for prepg. such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus, peptide II was prepd. and showed Ki = 1-100 nM (category A) in the HCV continuous assay.

AN 2003:591204 CAPLUS

DN 139:149928

TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

IN Saksena, Anil K.; Girijavallabhn, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.

PA Schering Corporation, USA; Corvas International, Inc.

SO PCT Int. Appl., 633 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062265	A2	20030731	WO 2003-US1430	20030116
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI US 2002-52386	A	20020118		
OS MARPAT 139:149928				

IT 394721-05-2P 394721-06-3P 394721-07-4P
394721-08-5P 394721-21-2P 394721-22-3P
394721-23-4P 394721-46-1P 394721-47-2P
394721-48-3P 394721-50-7P 394721-51-8P
394721-56-3P 394721-57-4P 394721-58-5P
394721-60-9P 394721-76-7P 394721-82-5P
394721-85-8P 394721-86-9P 394721-94-9P
394721-95-0P 394721-96-1P 394721-97-2P
394721-98-3P 394721-99-4P 394722-00-0P
394722-02-2P 394722-03-3P 394722-04-4P
394722-05-5P 394722-06-6P 394722-07-7P
394722-16-8P 394722-23-7P 394722-24-8P
394722-25-9P 394722-36-2P 394722-39-5P
394722-45-3P 394722-47-5P 394722-58-8P
394722-60-2P 394722-70-4P 394722-72-6P
394722-73-7P 394722-74-8P 394722-78-2P
394722-79-3P 394722-80-6P 394722-81-7P
394722-87-3P 394722-88-4P 394722-89-5P
394723-42-3P 394723-46-7P 394723-54-7P
394723-55-8P 394723-67-2P 394723-68-3P
394723-82-1P 394723-91-2P 394723-99-0P
394724-78-8P 394724-80-2P 394724-83-5P
394724-84-6P 394724-89-1P 394724-90-4P
394724-91-5P 394724-92-6P 394724-93-7P
394724-98-2P 394724-99-3P 394725-00-9P
394725-01-0P 394725-02-1P 394725-06-5P
394725-92-9P 394725-94-1P 394725-96-3P
394726-02-4P 394726-18-2P 394726-19-3P
394726-92-2P 394730-97-3P 394734-46-4P
394734-47-5P 394734-67-9P 394734-68-0P
394734-69-1P 394734-70-4P 394734-71-5P
394734-72-6P 394740-17-1P 395644-64-1P
395648-98-3P 395649-09-9P 395649-10-2P
395649-14-6P 395649-15-7P 395649-18-0P
395649-19-1P 395649-25-9P 395649-26-0P
395649-31-7P 395649-33-9P 395649-37-3P
395649-38-4P 395649-65-7P 395650-48-3P
395650-84-7P 395652-02-5P 395652-23-0P
395652-86-5P 569678-05-3P 570376-36-2P
570376-37-3P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(prepn. of peptides as NS3-serine protease inhibitors of hepatitis C
virus)


RN 394721-05-2 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-6,10-
dithia-2-azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-2-
phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-06-3 CAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-07-4 CAPLUS
 CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394721-08-5 CAPLUS
 CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-
 6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-
 N-methoxy-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394721-21-2 CAPLUS
 CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(3S)-6,10-dithia-2-
 azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-2-phenyl-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394721-22-3 CAPLUS
 CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-2-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-23-4 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-46-1 CAPLUS
 CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxohexanoyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-47-2 CAPLUS
 CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-48-3 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-50-7 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN	394721-51-8	CAPLUS
CN	Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-D-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




RN	394721-56-3	CAPLUS
CN	Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4S)-3-amino-4-methyl-2-oxohexanoyl-, methyl ester (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




RN 394721-57-4 CAPLUS
CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4,4-difluoro-L-prolyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-58-5 CAPLUS
 CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4S)-3-amino-4-methyl-2-oxohexanoyl- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 394721-60-9 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4S)-3-amino-4-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 394721-76-7 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-azido-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394721-82-5 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(2S)-2-[[[1,1-dimethylethoxy]carbonyl]amino]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394721-85-8 CAPLUS

Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-(acetyl-amino)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394721-86-9 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-[(2-furanylcarbonyl)amino]-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 394721-94-9 CAPLUS
 CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394721-95-0 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1R)-2-[(2-furanylcarbonyl)amino]-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



RN 394721-96-1 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy) carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1R)-2-(acetamino)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394721-97-2 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1R)-2-azido-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394721-98-3 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3R)-3-amino-2-oxoheptanoyl-N-[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-phenylethyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394721-99-4 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S)-3-amino-2-oxoheptanoyl-N-[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-phenylethyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-00-0 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-5-methyl-2-oxohexanoyl-2-¹³C-glycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-02-2 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-03-3 CAPLUS

CN Glycine, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S)-3-amino-2-oxoheptanoyl-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 394722-04-4 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(2R)-2-amino-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-05-5 CAPLUS


CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-06-6 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-[(diphenoxyphosphinyl)oxy]-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-07-7 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-oxo-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-16-8 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-(aminooxoacetyl)pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-23-7 CAPLUS
CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-(2-thienyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-24-8 CAPLUS
CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-(2-thienyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-25-9 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-(2-thienyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394722-36-2 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(2S)-2-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394722-39-5 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394722-45-3 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-(3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394722-47-5 CAPLUS



CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-D-valyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-(3S)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394722-58-8 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-D-valyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-60-2 CAPLUS
 CN Glycinamide, N-[(2,2-dimethylpropoxy)carbonyl]-3-methyl-L-valyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394722-70-4 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy) carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-N-[(1S)-2-amino-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394722-72-6 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy) carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxoheptanoyl-N-[(1S,2S)-2-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-73-7 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-D-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxoheptanoyl-N-[(1S,2S)-2-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-74-8 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S,4R)-3-amino-4-methyl-2-oxoheptanoyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-78-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[(1,1-dimethylethyl)amino]oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-79-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[(cyclopropylamino)oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-80-6 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[(cyclopropylmethyl)amino]oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-81-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[[[2-(2-methoxyphenyl)ethyl]amino]oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-87-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[(methoxyamino)oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-88-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[(3-butenylamino)oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394722-89-5 CAPLUS


CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-2-[[[1-[(2-methoxyethyl)amino]oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394723-42-3 CAPLUS
 CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy) carbonyl]glycyl-
 (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-
 (.beta.S,1S,2R)-.beta.-amino-2-methyl-.alpha.-
 oxocyclopropanepropanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 394723-46-7 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy) carbonyl]-L-valyl-4,4-dimethyl-L-
 prolyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 394723-54-7 CAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,4-dimethyl-L-prolyl-(3S)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394723-55-8 CAPLUS

CN Glycinamide, 3-methyl-N-[(1-methylethoxy)carbonyl]-L-valyl-4,4-dimethyl-L-prolyl-(3S)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394723-67-2 CAPLUS

CN Glycinamide, (2S)-2-(1-methylcyclohexyl)-N-[(2-methylpropoxy)carbonyl]glycyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-(3S)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394723-68-3 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-(3S)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394723-82-1 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-N-[1-(aminooxoacetyl)pentyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394723-91-2 CAPLUS

CN Carbamic acid, [2-[(1R,3S,4S)-3-[[[1-(aminooxoacetyl)pentyl]amino]carbonyl]-2-azabicyclo[2.2.1]hept-2-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394723-99-0 CAPLUS

CN Carbamic acid, [(1S)-2-[(1R,2S,5S)-2-[[[1-(aminooxoacetyl)-3-methylbutyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394724-78-8 CAPLUS



CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(1S,3aR,4S,7R,7aS)-octahydro-4,7-methano-1H-isoindole-1-carbonyl-(3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394724-80-2 CAPLUS
 CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-
 (1S,3aR,4S,7R,7aS)-octahydro-4,7-methano-1H-isoindole-1-carbonyl-3-amino-2-
 oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394724-83-5 CAPLUS
 CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-
 (3aR,4S,6aS)-tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrole-4-
 carbonyl- (3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 394724-84-6 CAPLUS
 CN Glycinamide, N-[(1,1-dimethylethoxy) carbonyl]-3-methyl-L-valyl-
 (3aR,4S,6aS)-tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrole-4-
 carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 394724-89-1 CAPLUS
 CN Glycinamide, N-[(1,1-dimethylethoxy) carbonyl]-3-methyl-L-valyl-(4R)-4-(1,1-
 dimethylethoxy)-L-prolyl-(3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-
 phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394724-90-4 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-(3S)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394724-91-5 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394724-92-6 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4,4-dimethyl-L-prolyl-(3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394724-93-7 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4,4-dimethyl-L-prolyl-(3S)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394724-98-2 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(3-methylbutyl)-L-prolyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394724-99-3 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(3-methylbutyl)-L-prolyl-(3R)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394725-00-9 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(3-methylbutyl)-L-prolyl-(3S)-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394725-01-0 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4,4-dimethyl-L-prolyl-(3R)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394725-02-1 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4,4-dimethyl-L-prolyl-(3S)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394725-06-5 CAPLUS

CN Glycinamide, N-[[[(1S)-1,2-dimethylpropoxy]carbonyl]-3-methyl-L-valyl-4,4-dimethyl-L-prolyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394725-92-9 CAPLUS

CN Carbamic acid, [(1S)-2,2-dimethyl-1-[[[(3aR,4S,6aS)-tetrahydro-2,2-dimethyl-4-[[[1-[oxo(2-propenylamino)acetyl]pentyl]amino]carbonyl]-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]carbonyl]propyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 394725-94-1 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R,2S,5S)-6,6-dimethyl-2-[[[1-[oxo(2-propenylamino)acetyl]pentyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394725-96-3 CAPLUS

CN L-Prolineamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4-(1,1-dimethylethoxy)-N-[1-[oxo(2-propenylamino)acetyl]pentyl]-, (4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 394726-02-4 CAPLUS

CN L-Prolineamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-4,4-dimethyl-N-[1-[oxo(2-propenylamino)acetyl]pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394726-92-2 CAPLUS

CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(1R,2S,5S)-6,6-dimethyl-2-[[[3-methyl-1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394730-97-3 CAPLUS

CN Glycinamide, 3-methyl-N-[(1-methylethoxy)carbonyl]-L-valyl-(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-(3S)-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-46-4 CAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-47-5 CAPLUS

CN Glycinamide, (2S)-N-[(1,1-dimethylethoxy)carbonyl]-2-phenylglycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-67-9 CAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-prolyl-3-amino-2-oxoheptanoylglycyl-2-cyclohexyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-68-0 CAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-2-cyclohexyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-69-1 CAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-prolyl-3-amino-2-oxoheptanoyl-L-alanyl-2-cyclohexyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-70-4 CAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoyl-L-alanyl-2-cyclohexyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-71-5 CAPLUS

CN Glycinamide, 3-methyl-N-[(2-methylpropoxy)carbonyl]-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394734-72-6 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxoheptanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 394740-17-1 CAPLUS

CN Glycinamide, N-[(1S)-1,2-dimethylpropoxy]carbonyl]-3-methyl-L-valyl-4,4-dimethyl-L-prolyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 395644-64-1 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S)-2-[[[1-(aminooxoacetyl)-3-methylbutyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395648-98-3 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-(2-thienyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-09-9 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-(3-thienyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-10-2 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-2-(2,3-dihydro-1H-inden-2-yl)-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 395649-14-6 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methylvalyl-(1R,3S,4S)-2-

azabicyclo[2.2.1]heptane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-15-7 CAPLUS

CN Glycinamide, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-18-0 CAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1R,2R,4S,5S,7S)-6-azatricyclo[3.2.1.0^{2,4}]octane-7-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395649-19-1 CAPLUS
CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methylvalyl-
(1R,2R,4S,5S,7S)-6-azatricyclo[3.2.1.0^{2,4}]octane-7-carbonyl-3-amino-2-
oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395649-25-9 CAPLUS
CN Glycinamide, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-
(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carbonyl-3-amino-5-methyl-2-
oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-26-0 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methylvalyl-(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-31-7 CAPLUS

CN Glycinamide, 3-methyl-N-[(1-methylethoxy)carbonyl]-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-33-9 CAPLUS

CN Glycinamide, N-[[[(1R)-1,2-dimethylpropoxy]carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-37-3 CAPLUS

CN Glycinamide, 3-methyl-N-[(1-methylethoxy)carbonyl]-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 395649-38-4 CAPLUS

CN Glycinamide, N-[(cyclohexyloxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 395649-18-0 CAPLUS

CN Glycinamide, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-
(1R,2R,4S,5S,7S)-6-azatricyclo[3.2.1.0.2,4]octane-7-carbonyl-3-amino-2-
oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-19-1 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methylvalyl-
(1R,2R,4S,5S,7S)-6-azatricyclo[3.2.1.0.2,4]octane-7-carbonyl-3-amino-2-
oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-25-9 CAPLUS

CN Glycinamide, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-26-0 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methylvalyl-(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-31-7 CAPLUS

CN Glycinamide, 3-methyl-N-[(1-methylethoxy)carbonyl]-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-33-9 CAPLUS

CN Glycinamide, N-[[[(1R)-1,2-dimethylpropoxy]carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-5-methyl-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395649-37-3 CAPLUS

CN Glycinamide, 3-methyl-N-[(1-methylethoxy)carbonyl]-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-38-4 CAPLUS

CN Glycinamide, N-[(cyclohexyloxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395649-65-7 CAPLUS

CN Glycinamide, N-[[[(1R)-1,2-dimethylpropoxy]carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395650-48-3 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dibromo-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxoheptanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395650-84-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S)-2-[[[1-[(methoxyamino)oxoacetyl]pentyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395652-02-5 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S)-6,6-dimethyl-2-[[[3-methyl-1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395652-23-0 CAPLUS

CN Carbamic acid, [(1S)-1-(2,3-dihydro-1H-inden-2-yl)-2-[(2S)-6,6-dimethyl-2-[[[3-methyl-1-[[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395652-86-5 CAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(2S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-5-methyl-2-oxohexanoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Chemical structure of compound 10, showing a complex molecule with a bicyclic system, a sulfur atom, a carbonyl group, and a side chain containing a cyclopentyl ring, a carbonyl group, and a chiral center with a phenyl group and a dimethylamino group.

RN	570376-36-2	CAPLUS
CN	Carbamic acid, [(1S)-1-cyclohexyl-2-[(1R,2S,5S)-6,6-dimethyl-2-[[[1-[oxo(2-propenylamino)acetyl]pentyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 3-methylcyclopentyl ester (9CI) (CA INDEX NAME)	

The chemical structure is a complex molecule featuring several interconnected rings and functional groups. At the top, a cyclohexyl ring is attached to a sulfur atom (S), which is part of a chain containing an amide group (NH-C=O) and an ether linkage (O) to a cyclopentyl ring substituted with a methyl group (Me). Below this, a bicyclic system is shown, consisting of a five-membered ring fused to a six-membered ring, both containing sulfur atoms (S). This bicyclic system is connected to a chain that includes another amide group (NH-C=O) and a prop-1-en-1-yl group (CH=CH-CH₂). The structure also includes a cyclohexyl ring, a cyclopentyl ring, and a bicyclic system with two sulfur atoms. The overall structure is a complex molecule with multiple functional groups and rings.

RN 570376-37-3 CAPLUS

CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(1R,2S,5S)-6,6-dimethyl-2-[[[1-[oxo(2-propenylamino)acetyl]pentyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 2-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

